Experienced in Secondary Immunodeficiency (SID)

Marten Trendelenburg

Basel, BS, CH 
Experienced in Secondary Immunodeficiency (SID)
Basel, BS, CH 
OverviewLocationsClinical Research

Overview

Marten Trendelenburg practices in Basel, Switzerland. Mr. Trendelenburg is rated as an Experienced expert by MediFind in the treatment of Secondary Immunodeficiency (SID). His top areas of expertise are Complement Component 2 Deficiency, Systemic Lupus Erythematosus (SLE), Lupus Nephritis, Glomerulonephritis, and Thymectomy.

His clinical research consists of co-authoring 96 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Secondary Immunodeficiency (SID).

Gender
Male

Locations

Basel, BS, Switzerland

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

Recombinant Human C1 Esterase Inhibitor (Conestat Alfa) in the Prevention of Severe SARS-CoV-2 Infection in Hospitalized Patients With COVID-19: a Randomized, Parallel-group, Open-label, Multi-center Pilot Trial (PROTECT-COVID-19).
Recombinant Human C1 Esterase Inhibitor (Conestat Alfa) in the Prevention of Severe SARS-CoV-2 Infection in Hospitalized Patients With COVID-19: a Randomized, Parallel-group, Open-label, Multi-center Pilot Trial (PROTECT-COVID-19).
Enrollment Status: Terminated
Publish Date: November 09, 2021
Intervention Type: Drug
Study Drug: Conestat alfa
Study Phase: Phase 2
Trauma as a Trigger for Autoimmunity - a Single Centre Observational Cohort Study
Trauma as a Trigger for Autoimmunity - a Single Centre Observational Cohort Study
Enrollment Status: Completed
Publish Date: April 07, 2020
Intervention Type: Diagnostic test
Recombinant Human C1 Esterase Inhibitor (Conestat Alfa) in the Prevention of Contrast-induced Nephropathy in High-risk Subjects (PROTECT): a Randomized, Placebo-controlled, Double-blind Single-center Trial
Recombinant Human C1 Esterase Inhibitor (Conestat Alfa) in the Prevention of Contrast-induced Nephropathy in High-risk Subjects (PROTECT): a Randomized, Placebo-controlled, Double-blind Single-center Trial
Enrollment Status: Completed
Publish Date: August 08, 2018
Intervention Type: Drug
Study Phase: Phase 2
View 2 Less Clinical Trials

96 Total Publications

A case of constrictive pericarditis and cryoglobulinemic vasculitis in a patient with Whipple's disease.
A case of constrictive pericarditis and cryoglobulinemic vasculitis in a patient with Whipple's disease.
Journal: The American journal of medicine
Published: August 16, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Trendelenburg's expertise for a condition
ConditionClose
    View All 19 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile